A Phase 3, Randomized, Open-Label, Parallel-Group Study to Compare the Pharmacodynamics, Pharmacokinetics, Efficacy, Safety, Tolerability, and Immunogenicity of Multiple Subcutaneous Injections of Efg

Administered By

Awarded By

Contributors

Start/End

  • May 19, 2021 - May 18, 2026